Duligotuzumab

Duligotuzumab
Monoclonal antibody
Type Whole antibody
Source Human
Target HER3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none

Duligotuzumab (INN) is a humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER3.[1] It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.[2]

References

  1. ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  2. ↑ "Duligotuzumab". AdisInsight.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.